7DZW
Apo spike protein from SARS-CoV2
Summary for 7DZW
| Entry DOI | 10.2210/pdb7dzw/pdb |
| EMDB information | 30915 |
| Descriptor | Spike glycoprotein (1 entity in total) |
| Functional Keywords | sars-cov2, spike protein, viral protein |
| Biological source | Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2) |
| Total number of polymer chains | 3 |
| Total formula weight | 415160.34 |
| Authors | Liu, Y.,Soh, W.T.,Li, S.,Kishikawa, J.,Hirose, M.,Kato, T.,Standley, D.,Okada, M.,Arase, H. (deposition date: 2021-01-26, release date: 2021-06-02, Last modification date: 2024-03-27) |
| Primary citation | Liu, Y.,Soh, W.T.,Kishikawa, J.I.,Hirose, M.,Nakayama, E.E.,Li, S.,Sasai, M.,Suzuki, T.,Tada, A.,Arakawa, A.,Matsuoka, S.,Akamatsu, K.,Matsuda, M.,Ono, C.,Torii, S.,Kishida, K.,Jin, H.,Nakai, W.,Arase, N.,Nakagawa, A.,Matsumoto, M.,Nakazaki, Y.,Shindo, Y.,Kohyama, M.,Tomii, K.,Ohmura, K.,Ohshima, S.,Okamoto, T.,Yamamoto, M.,Nakagami, H.,Matsuura, Y.,Nakagawa, A.,Kato, T.,Okada, M.,Standley, D.M.,Shioda, T.,Arase, H. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell, 184:3452-3466.e18, 2021 Cited by PubMed Abstract: Antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein prevent SARS-CoV-2 infection. However, the effects of antibodies against other spike protein domains are largely unknown. Here, we screened a series of anti-spike monoclonal antibodies from coronavirus disease 2019 (COVID-19) patients and found that some of antibodies against the N-terminal domain (NTD) induced the open conformation of RBD and thus enhanced the binding capacity of the spike protein to ACE2 and infectivity of SARS-CoV-2. Mutational analysis revealed that all of the infectivity-enhancing antibodies recognized a specific site on the NTD. Structural analysis demonstrated that all infectivity-enhancing antibodies bound to NTD in a similar manner. The antibodies against this infectivity-enhancing site were detected at high levels in severe patients. Moreover, we identified antibodies against the infectivity-enhancing site in uninfected donors, albeit at a lower frequency. These findings demonstrate that not only neutralizing antibodies but also enhancing antibodies are produced during SARS-CoV-2 infection. PubMed: 34139176DOI: 10.1016/j.cell.2021.05.032 PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (3.45 Å) |
Structure validation
Download full validation report
